Where Zentalis Pharma Stands With Analysts
Portfolio Pulse from Benzinga Insights
In the past 3 months, 4 analysts have published their opinions on Zentalis Pharma (NASDAQ:ZNTL) stock, with an average 12-month price target of $57.5, a 52.08% decrease from the previous average of $120. The company has received 3 bullish and 1 somewhat bullish ratings.
May 19, 2023 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zentalis Pharma (NASDAQ:ZNTL) has an average 12-month price target of $57.5, a 52.08% decrease from the previous average of $120, with 3 bullish and 1 somewhat bullish ratings from 4 analysts.
The average 12-month price target for Zentalis Pharma has decreased significantly, which may indicate a change in analysts' outlook on the stock. However, the majority of the ratings are still bullish or somewhat bullish, suggesting that the stock may not experience a significant short-term price movement. The neutral score reflects the mixed signals from the decrease in price target and the overall positive ratings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100